Organisation paid for research Program year 2022 Source: CMS Open Payments

Emory University Internal Audit Division

Neither a doctor nor a teaching hospital

Research payments

$1,326,815

19 payments

Through program year 2022, Emory University Internal Audit Division is reported as receiving $1,326,815 in research payments, across 19 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$1,077,239	9
2020	Research	$62,718	4
2019	Research	$186,857	6

Breakdown

Who paid Research payments · program years 2019–2022

Biogen, Inc. $1,077,239 9 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $249,575 10 payments

Studies the money was for Research payments · program years 2019–2022

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect of Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation $267,590 1 payment
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety,Tolerability, and Pharmacokinetics of BIIB105 Administered Intrathecally to AdultsWith Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in theAtaxin-2 Gene $249,530 1 payment
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $234,047 1 payment
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis $153,764 1 payment
A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension $65,189 1 payment
Exercise capacity study in HFrEF $62,519 2 payments
An Extension Study to Assess the Long-Term Safety, Tolerability,Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered toPreviously Treated Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis $59,873 1 payment
Extension $46,188 1 payment
Exercise capacity study in HFpEF $39,580 2 payments
Nintedanib PF ILD $32,994 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.